Skip to Content

Join the 'Neutropenia Associated with Chemotherapy' group to help and get support from people like you.

Neutropenia Associated with Chemotherapy News

Chemo May Worsen Quality of Life for End-Stage Cancer Patients

Posted 23 Jul 2015 by Drugs.com

THURSDAY, July 23, 2015 – Chemotherapy may worsen quality of life for some cancer patients who are nearing death, a new study finds. "Oncologists may presume there to be no harm in giving dying patients chemotherapy, but these data point to more harm than benefit," study author Dr. Holly Prigerson, from Weill Cornell Medical College in New York City, said in a college news release. The research included more than 300 patients with advanced cancer who had about four months to live. Their average age was about 59. About half of the patients were receiving what's known as palliative chemotherapy when the study began. Palliative chemotherapy is generally given to people who have fewer than six months to live, according to the researchers. The hope is that palliative chemotherapy will ease symptoms and extend survival. But that wasn't the case for those patients who started the study with ... Read more

Related support groups: Cancer, Breast Cancer, Metastatic, Nausea/Vomiting - Chemotherapy Induced, Breast Cancer - Palliative, Neutropenia Associated with Chemotherapy, Hyperuricemia Secondary to Chemotherapy, Anemia - Chemotherapy Induced

First Biosimilar Drug Zarxio (filgrastim-sndz) Approved

Posted 8 Mar 2015 by Drugs.com

FRIDAY, March 6, 2015 – The U.S. Food and Drug Administration has approved the first "biosimilar" drug, meaning it is a biologic product that is "highly similar" to an already approved medication. Clinical studies showed Zarxio (filgrastim-sndz) had "no clinically meaningful" difference in safety and effectiveness from the anti-cancer drug Neupogen that was approved in 1991, the FDA said Friday in a news release. "Only minor differences in clinically inactive components are allowable in biosimilar products," the agency said in clarifying its definition of a biosimilar drug. Zarxio is approved for the same indications as the already-sanctioned drug, including: People with cancer who are on myelosuppressive chemotherapy. People with acute myeloid leukemia who are on induction or consolidation chemotherapy. People with cancer who are having bone marrow transplant. People who are having ... Read more

Related support groups: Neutropenia Associated with Chemotherapy

FDA Approves First Biosimilar Product Zarxio (filgrastim-sndz)

Posted 6 Mar 2015 by Drugs.com

March 6, 2015 – The U.S. Food and Drug Administration today approved Zarxio (filgrastim-sndz), the first biosimilar product approved in the United States. Biological products are generally derived from a living organism. They can come from many sources, including humans, animals, microorganisms or yeast. A biosimilar product is a biological product that is approved based on a showing that it is highly similar to an already-approved biological product, known as a reference product. The biosimilar also must show it has no clinically meaningful differences in terms of safety and effectiveness from the reference product. Only minor differences in clinically inactive components are allowable in biosimilar products. Sandoz, Inc.’s Zarxio is biosimilar to Amgen Inc.’s Neupogen (filgrastim), which was originally licensed in 1991. Zarxio is approved for the same indications as Neupogen, and c ... Read more

Related support groups: Neupogen, Neutropenia, Neutropenia Associated with Chemotherapy, Filgrastim

FDA Approves Teva’s Granix (tbo-filgrastim) Injection for Self-Administration

Posted 24 Dec 2014 by Drugs.com

JERUSALEM, December 23, 2014--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved Granix (tbo-filgrastim) Injection for self-administration by patients and caregivers. With the approval of this additional administration option, physicians will soon have the flexibility to prescribe Granix for either in-office or at home use. “This new administration option demonstrates Teva’s continued commitment to enhancing the patient experience by providing patients, in partnership with their physician, with flexibility in their treatment regimen” Granix, a leukocyte growth factor, is indicated for reduction in the duration of severe neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. Grani ... Read more

Related support groups: Neutropenia Associated with Chemotherapy, Tbo-filgrastim

FDA Approves Tbo-filgrastim for Severe Neutropenia in Certain Cancer Patients

Posted 1 Sep 2012 by Drugs.com

August 29, 2012 – The U.S. Food and Drug Administration today approved Sicor Biotech’s tbo-filgrastim to reduce the time certain patients receiving cancer chemotherapy experience severe neutropenia, a decrease in infection-fighting white blood cells called neutrophils. Tbo-filgrastim is intended for use in adults who have cancers other than blood or bone marrow cancers (non-myeloid malignancies) and are taking chemotherapy drugs that cause a substantial decrease in the production of neutrophils in the bone marrow. This reduction in neutrophils may lead to infection and fever (febrile neutropenia). Tbo-filgrastim stimulates the bone marrow to increase the production of neutrophils. It is administered as an injection beginning 24 hours after chemotherapy treatment. “Supportive care products, such as tbo-filgrastim, reduce or allow for more rapid recovery from side effects of cancer tre ... Read more

Related support groups: Neutropenia, Neutropenia Associated with Chemotherapy, Filgrastim

Ask a Question

Further Information

Related Condition Support Groups

Neutropenia

Related Drug Support Groups

Neulasta, Neupogen, Leukine, pegfilgrastim, tbo-filgrastim, filgrastim, Zarxio, sargramostim, Granix